Aug 21, 2012|
Holley and Ordway greet Jay Thompson, who was diagnosed with gastrointestinal stomal tumors, and his doctor, George Demetri, the director of the Center for Sarcoma and Bone Oncology at Dana-Farber. Jay talks about how some simple stomach issues turned out to be tumors in his stomach lining and his battle to stop the growth of the inoperable cancer.
Transcript - will not be 100% accurate
Jake Thompson. Is the patient doctor George Dmitry is the position we'll start with you Jay first of all it's great to meet Abbott's no border it says here. -- -- -- -- -- -- -- -- -- -- So it's not that they of those slow forty cycle now I haven't they can do not -- -- when we first diagnosed tomorrow we diagnosed with. I was diagnosed back in May of 09. With gastrointestinal. -- I would do feel like tell us what you were feeling and why you picked up the phone call the doctor. Actually had an -- In my stomach on the primary location. Had quite a bit of pain for a few days I don't -- -- They see if I could've been -- for a few days and and then finally got to the point where I was having difficulty eating so right. Called my primary care physician and he got -- in and bring a much tests and one thing led to another and that day we were. Ninety isn't sure what those are dealing with and you were dealing with. The gastrointestinal. Struggled tumors gist for short emotionally how did you feel like they what did you know about it what did you learn shortly after that. I didn't know anything about it never heard of it. That day I didn't feel alive I think it was still kind of it did definitely took a few days to sink in. Those remarkably relaxed that first day. We -- I just because they've. Was. Surrounded with such good people that I knew those him in good hands and headed in the right direction. But I started reading up about it of course when you go online and you start reading about it all sounds very scary it's not until you. Get to a place like Dana Farber and you work was. Doctor Dmitry. Doctor Suzanne George will work with -- bases that you start to learn more more about it what's been going on for the past. 101520 years in in research and development. To find ways for of the cure for these things. Prior -- good transition because her doctor wanna ask you how has our research. Changed in ten or fifteen years and well what he's dealing with what he had dealt with the 2009. What would have been the story in 1999. -- in 1989 we had nothing to treat this disease this was the kind of cancer and against cancer a bad name. Because no matter what we would do he wouldn't work and then in a year 2000 type team and some mothers we collaborated with across the world. Figured out the short circuit in this -- came up with a series of drugs and has now been FDA approved. And are helping people people like. In the year 2000 might have only had six weeks to live I -- one of them today twelve years later still taking. The medicine that we developed back in year 2000. And it's all because of the kind of research and Dana Farber does to take that science can turn into effective new treatments and the only way we can do that because of generosity of people like -- was willing to drive up from Connecticut to be here today. To show his support for Dana Farber. And for the people in New England to really support Dana Farber and really. Help us to do we wanna do I should mention that. -- -- we're talking about some of the cutting edge technology that doctor Demetrius also the senior vice president for experimental. Therapeutics. And what are you guys are doing right now this is cutting edge that we can look at down the road in the next year or two. We're we're doing so many things they can't even describe it these are appeals -- taking -- -- That can really show nothing short circuits were developing skills like that. For breast cancer we're developing ways of turning on the immune system. To fight cancer with the body's natural defense is -- -- we couldn't even imagine a possible five or ten years ago. I know in clinical trials and Dana Farber. On the way to get FDA approved and it's all because the research research comes in many times not just people looking in my small laboratory. The kind of research I do with patience -- is actually on a clinical research trial. And it's allowed us to get him a drug. Before it's FDA approved in fact part of the trial he did his part of that data that suggests that this drug does work -- the FDA will review it. Can say hopefully make sure that works well enough to -- indeed seal of approval and let people have had it for commercial standard US. In in this journey -- that you've gone through me wouldn't. But what was it like funeral for you guys to learn it. Oh my god and I have this I have just which I've never heard of him and now this opens up a whole new chapter for ourselves and I think guys. Well tough. Tough question to answer hard to put into words. I had no problem telling people that it -- gifted tables were turned or if I had a choice of which one of us got sick I would get I would -- -- cancer every time I don't quite understand how she manages to deal with this is Willis she does. She's incredibly supportive. And in keeps me on track. Daily weekly you know this this whole journey has has been one that we've been through very much together. And one and certainly wouldn't be. Dealing with nearly as well without her help. But I don't know how she does it quite frankly. And she still works pretty well tuned yes so most of my time trying to keep over there. -- how you -- these -- a pretty good. I very little to complain about and you take these pills are there any after effects the pills do you have any that's fluid there -- -- Forty -- what happens. Hey you know it it varies. How it. It's fairly consistent but I think sometimes you know as big chemistry in my body varies from one month to the next my side effects -- very little bit. The most commonly I have like hand and then -- reactions tonight. And hands and -- -- kind of -- Lauren and I feel like they've been sunburned from things like that. Some which -- won't discuss on the here and thank you. -- US. Expressing legitimate program right right into the. Because I think that down. I write any more reason I don't I don't have a lot to complain you know so. That being said well listen we're really happy you went to the right plus there's no question about that I only found now. And no hopefully you're on a great road to recovery here we thank you for coming in here and coming up from Connecticut sharing your stories. The doctor is always great seeing you and I continued success of the great work did you guys do over there especially that research that you're doing. Because it's all of the new discoveries that are going to -- as you said turn on and off various systems within our body. They don't change showed the lives of our guys like.
WEEI.com's Mike Petraglia and Chris Price discuss the latest development at Patriots training camp. Chris says Darrelle Revis has looked great, and that his impact on the defense is actually being underplayed nationally.
WEEI.com's Mike Petraglia and Chris Price discuss Rob Gronkowski's meeting with the media on Friday. Gronk said he doesn't anticipate changing the way he plays, noting that he wants to "keep smashing and dashing."
Julian Edelman joins Merloni, Fauria, and Benz after Patriots training camp.
Jackie Mac joins the guys to discuss her thoughts on a possible mid-season tournament in the NBA, LeBron's return to Cleveland, trade rumors with the Celtics and Red Sox, and Darrelle Revis' contract situation.
Jackie MacMullan of ESPN Boston to talk about the Lebron James Saga, the possibility of Rajon Rondo being traded, and the future of Marcus Smart.
Former coach of Celtics 1st-round pick Marcus Smart, Travis Ford joins MFB to talk about what Celtics fans should expect from the strong point guard. Among other things, Coach Ford says Smart will be a hard worker, and will improve his shooting ability.
Tim Kurkjian joins the program to discuss the Red Sox options at the trade deadline.
Kevin Millar joins Merloni, Fauria, and Benz to discuss David Ortiz, Dustin Pedroia's struggles, and Jon Lester's contract.
Rob Bradford is joined by WEEI.com Bruins beat writer DJ Bean, as well as Boston sports fan/blogger Turtleboy to talk all things Bruins free agency. With the B's recent moves, the conversation turns to where the Bruins might next turn and what kind of dent losing Jarome Iginla and Shawn Thornton might make.
DJ discusses Shawn Thornton's new deal, and the on going negotiations with Jerome Iginla
DJ Bean joins the program to dismiss the recent rumors that the Bruins are in discussions to trade Brad Marchand to the Sharks for Patrick Marleau
John, Gerry, and Steve DeOssie discuss Tom Brady's impact on the rest of the Patriots, plus Steve tells tales from his old days as a NFL linebacker
A whale watch boat is stranded overnight in Boston Harbor
Clay Buchholz and Felix Doubront certainly put on quite the pitching performance, as the Red Sox were trounced by the Jays. Does this change the team's approach to the trade deadline?
Christian tells a story about taking his girlfriend to see "Jersey Boys" in NYC, but he leaves out some crucial details. Luckily, she was listening and called the show to clarify exactly what kind of shenanigans he was trying to pull.
MFB discuss a Peter King article that suggests many NFL coaches and assistant coaches have felt increasing pressure over big-money fantasy football players. Christian also weighs in specifically on how his knowledge of game-plans resulted directly in him winning his first season as a fantasy football player.
The Sox lost 14-1 as Clay Buchholz and Felix Doubront both had awful performances. On the heels of the loss, rumors began to fly regarding Jon Lester and John Lackey possibly being traded.
We talk about the latest news surrounding Jon Lester and the Red Sox. Could he be dealt to the Dodgers?
We talk about four of the biggest mistakes the Red Sox have made over the past 30+ years.
We discuss the return of Rob Gronkowski, his comments to the media today, and what a healthy (or unhealthy) Gronk will mean for the 2014 Patriots.
Mut and Villani are talking about whether the Red Sox will give Jon Lester the type of contract he is looking for, or whether they might be shopping him with rumors of the Red Sox scouting Cole Hamels.
Mut and Villani are talking about the MLB All Star Game, Adam Wainwright and Derek Jeter, and what are some of the worst ideas in sports.
Sam and Zach discuss changing the format of the Podcast, the Chris Archer-David Ortiz debacle, and LeBron James being a super genius
Particularly in a year where the Red Sox have struggled while trying to integrate numerous young players into regular big league roles, accusations that Red Sox prospects are overrated -- whether by the team or writers -- have been widespread. Jim Callis of MLB.com joins the show to take stock of the matter, and to discuss the team-building impact of overrating and underrating prospects.
With the trade deadline looming, the next few days will be defined by how teams value prospects -- and their potential long-term contributions -- against big leaguers with established track records who can address immediate needs. Are prospects being valued accurately? Red Sox left-hander Andrew Miller -- once one of the two key chips that sent Miguel Cabrera from the Marlins to the Tigers -- assesses the matter.
Rob gave the latest on Jon Lester trade talks and the flap between Ortiz and the Rays.More from this show
Particularly in a year where the Red Sox have struggled while trying to integrate numerous young players into regular big league roles, accusations that Red Sox prospects are overrated -- whether by the team or writers -- have been widespread. Jim Callis of MLB.com joins the show to take stock of the matter, and to discuss the team-building impact of overrating and underrating prospects.More from this show
We talk about the latest news surrounding Jon Lester and the Red Sox. Could he be dealt to the Dodgers?More from this show